Articles tagged with Human Immunodeficiency Virus
A new assay detects intact HIV latent proviruses at higher frequencies than previous methods, revealing a significant amount of intact virus in infected individuals; this finding is crucial for developing an HIV cure. The study provides a benchmark for assessing persistent proviral DNA and its composition.
A GW-led research team is investigating HIV-1 resistance to antibody treatments, aiming to develop effective combination therapies for treatment, prevention, and potential cure. The project, funded through April 2025, aims to identify effective combination antibody cocktails that limit the virus's ability to escape from antibody pressure.
Physicists at University of Utah pioneered a method to image virus-like particles in real time, revealing the lattice's dynamic nature. The discovery opens up potential new therapies by understanding how Gag and GagPol proteins rearrange, leading to viral maturation.
A national quality improvement collaborative found that making primary care practices more inclusive improves STD and HIV screening rates among LGBT individuals. The program increased estimated HIV screening from 14.8% to 30.5% at participating sites.
A study by Rutgers researchers found that 19% of participants had their first sexual experience before age 13, with same-sex encounters happening on average at 14.5 years.
A large study found increased risk of heart disease, chronic liver and kidney disease, and physical function impairment in people with HIV. The study aims to develop effective prevention strategies and guidelines for cardiovascular risk management in this population.
A new study identifies key steps toward establishing nurse- and midwife-led HIV services in eastern and southern Africa, including improved training, supportive supervision, and formal mentorship programs. The region has shown remarkable progress toward eliminating HIV, but challenges remain in providing effective antiretroviral therapy.
The HPTN 083 clinical trial showed that a long-acting cabotegravir injection was superior to daily oral tenofovir/emtricitabine for HIV prevention among cisgender men and transgender women. The study found a 66% reduction in incident HIV infections in participants given cabotegravir compared to TDF/FTC.
A new long-acting injectable form of PrEP containing cabotegravir outperformed a daily oral Truvada regimen in preventing HIV acquisition among men who have sex with men and transgender women. The study found that the injectable PrEP had a superior protective effect, with a 66% lower incidence rate compared to the daily pill.
A Rutgers-led study finds that incarceration and police discrimination contribute to higher rates of psychological distress, HIV risk, and lower willingness to take PrEP among Black gay, bisexual, and other sexual minority men. The research highlights the need for anti-racist and anti-heterosexist advocacy and interventions to address ...
Researchers found that HIV-positive adults' brains process speech cues differently, with disrupted responses even when hearing tests are normal. This non-invasive test holds promise for understanding brain dysfunction in HIV and other disorders.
Researchers report a lower incidence of COVID-19 among HIV-positive patients receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) therapy. Further investigation is warranted to understand the findings' implications for HIV preexposure prophylaxis and randomized trials.
Yale researchers identified four approved drugs that can suppress HIV reactivation and reduce damaging immune responses. These drugs, including ruxolitinib and mycophenolic acid, show promise as a complement to antiretroviral therapy in treating HIV infection.
Scientists at Sanford Burnham Prebys have developed a new drug called Ciapavir that effectively reactivates dormant human immunodeficiency virus (HIV) without overactivating the immune system. This approach, called 'shock and kill,' aims to create a functional HIV cure by eliminating all pockets of dormant HIV.
The Pew Charitable Trusts has selected 10 postdoctoral fellows from seven Latin American countries to conduct research in the US. The fellows will explore various biomedical topics, including leukemia stem cells and HIV hiding inside host cells.
Researchers found that astrocytes in the brain can harbor HIV and spread it to immune cells that travel to other organs, even when treated with combination antiretroviral therapy. The study suggests that HIV reservoirs in the brain must be targeted for effective cure strategies.
New studies from Flinders University highlight key areas for improvement in HIV management in developing countries, particularly in sub-Saharan regions. Nutritional programs should address underlying challenges like poverty and food insecurity, while prisons often struggle with optimal HIV care due to stigma and resource limitations.
Researchers at Yale University have discovered a molecular explanation for how HIV hides in immune system cells, allowing it to remain dormant and re-emerge. By understanding this process, scientists may develop new ways to control HIV infection.
A new type of vaccination has been shown to substantially enhance and sustain protection from HIV in monkeys, with a two-armed approach stimulating both serum and cellular immunity. The findings have broad implications for immunologists pursuing vaccines for other diseases, particularly those caused by coronaviruses.
Researchers found that L-thyroxine therapy did not improve symptoms, quality of life, or handgrip strength in older adults with subclinical hypothyroidism and high symptom burden. This study's results do not support routine use of L-thyroxine for this population.
Researchers have identified a new potential reservoir of latent HIV, specifically CD127 cells in tissues, which harbor the virus's genetic material but silence its expression. These cells may be targeted for an HIV cure, offering hope for developing an effective treatment.
New research on the structure of HIV has revealed a promising novel drug target that can prevent further infection by targeting the genetic code. This discovery offers hope for more effective treatments and potentially fewer side effects for HIV patients.
A qualitative study found that women living with HIV prefer long-acting injectable (LAI) antiretroviral therapy due to its convenience, privacy, and perceived effectiveness. However, they also raised concerns about access, mistrust, and medical burden.
Research highlights increased cardiovascular disease risk among people with HIV worldwide, particularly in sub-Saharan Africa. The study explores how geographic location and income level influence the distribution of cardiovascular risk factors, shedding light on potential differences between lower- and higher-income countries.
Researchers identified a key HIV mechanism for viral adaptation to immune milieus. Lower Rev-RRE activity has been linked to slower disease progression and immune evasion, highlighting the potential for therapeutic targets.
Researchers have successfully developed a new, efficient method to create water-soluble fullerene compounds with high anti-HIV activity. This breakthrough could pave the way for new-generation drugs based on these compounds, offering hope for treating human immunodeficiency virus (HIV).
A multinational study of over 640 pregnant women with HIV found that regimens containing dolutegravir were more effective in suppressing HIV than a commonly used regimen containing efavirenz. Nearly 98% of women who received either of the DTG-containing regimens were virally suppressed at delivery, while only 91% of those receiving EFV...
A study of a second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy. The patient had a healthy CD4 cell count, suggesting they have recovered well from the transplant.
A new approach using harmless viruses to deliver antibody genes has led to sustained production of HIV antibodies for over a year in a NIH clinical trial. The technology shows promise for preventing and treating various infectious diseases with further development.
Researchers found that a community-based intervention using mobile vans significantly increased viral suppression, with 74% of participants achieving suppression compared to 63% in traditional clinics. The convenience of the vans made it easier for people living with HIV to access treatment.
Researchers found that starting ART immediately after HIV infection significantly reduces viral reservoirs, making them 100 times smaller. This discovery provides new hope for eradicating the virus.
People living with HIV in Ontario have a 34% higher incidence rate of COPD, diagnosed at 50 years old vs. 62 for HIV-negative individuals, according to a study led by St. Michael's Hospital researchers. The study also found that women with HIV have a 54% higher risk of COPD.
A recent study published in the journal AIDS found that vitamin E improves liver function and reduces fat in patients with nonalcoholic steatohepatitis (NASH) and HIV. The treatment was well-tolerated and showed more significant improvements than reported in the general population.
A new study finds that fewer than one in four gay, bisexual and questioning teenage boys have ever received an HIV test, despite high risk of transmission. The study identified factors that increase the likelihood of testing, including frank conversations with doctors about sexual health and testing.
A digital intervention program called Run4Love, tested on the popular Chinese social media app WeChat, significantly reduced depressive symptoms and stress among people living with HIV. The study found a promising approach to addressing mental health gaps in resource-limited settings.
A new study called DELIVER will enroll 750 healthy, HIV-negative pregnant women to test the safety of two HIV prevention methods: a monthly dapivirine vaginal ring and daily Truvada. The study aims to provide much-needed information about these products' safety in pregnant women, an area currently lacking in data.
A study from George Washington University found that apolipoprotein A-I binding protein (AIBP) inhibits HIV-1 replication by targeting lipid rafts and reducing virus-cell fusion. This innate immunity factor provides a novel target for developing new therapeutic approaches to inhibit HIV infection.
A study of over 1,000 youth found that only 12% achieved viral suppression, compared to 32-63% in adult studies. The study highlights the need for tailored HIV intervention services and frequent contact with trained peer counselors to ensure enrollment and retention in care.
A Phase 2b/3 study in South Africa found that an investigational prime-boost vaccine regimen did not prevent HIV, but participants were safe. Researchers are continuing to explore other approaches to a safe and effective HIV vaccine.
Researchers have found that combining two anti-HIV antibodies with ART can suppress the virus and boost T cell responses, offering new hope for HIV treatment. The study suggests a potential interaction between humoral immunity and cell-mediated immunity, which could lead to improved control of the virus.
Researchers calculated average initial HIV ART regimen costs from 2012 to 2018, finding a significant decrease in some regions and a steady increase in others. The study highlights the impact of high ART costs on HIV treatment outcomes in the US.
Patients living with HIV who attend religious services regularly experience higher emotional and physical well-being, while privately religious individuals face mental health challenges. Researchers suggest integrating spiritual beliefs into holistic treatment programs to improve health outcomes.
A novel HIV antibody, 1-18, has been identified as a highly potent and effective treatment option. Unlike other antibodies, it prevents the development of viral resistance, maintaining suppressed viral loads for extended periods.
Researchers discovered the structure of HIV intasomes while they were blocked by key drugs, revealing how these medications inhibit viral infection. The study provides valuable information to design and improve future treatments.
A new study suggests that state-purchased insurance plans are improving HIV outcomes for people living with the disease. The research found that increased enrollment in these programs is associated with better viral suppression rates, which can lead to a reduction in new HIV transmissions and healthcare costs.
Scientists at UNC-Chapel Hill and Emory University successfully reversed HIV latency in animal models using compound AZD5582. The study, published in Nature, demonstrated the ability to activate latently infected CD4+ T cells without toxicity, paving the way for further research towards a cure.
Scientists reactivated resting immune cells infected with HIV or SIV, allowing viruses to be neutralized by anti-HIV drugs and the immune system. The study uses a compound called AZD5582, which activates latent cells without causing toxicity.
A new study found HIV hides in every organ site, including the brain and liver, causing inflammation-related diseases. The study used serial blood samples from terminally ill participants with HIV to identify where HIV hides, shedding light on potential new therapies.
Researchers found that hotspots are not sources of infection but rather sinks for the virus, with more infections originating from outside communities. Inland communities with lower HIV prevalence drove more new infections in hotspot areas.
Experts argue against switching from Truvada to Tenofovir Alafenamide for PrEP, citing limited data on the newer drug's effectiveness in diverse populations. The current medication, Truvada, has been shown to be safe and effective with ample evidence of its safety and effectiveness.
The Otago Global Health Institute is investing in new research initiatives with the Fiji National University and the National University of East Timor. The collaborations aim to lay the foundation for long-term research collaborations and tackle health issues such as antibiotic-resistant bacteria, non-communicable diseases, and HIV.
Researchers at Norwegian University of Science and Technology have found a previously unknown way for the immune system to detect and respond to HIV infection. This discovery may hold the key to allowing the 'shock-and-kill' approach to work, where the virus is activated to be visible to the immune system and then killed.
A study co-led by Queen Mary University of London found that routine HIV screening in general practice increases testing rates and improves detection of earlier diagnosis. The analysis showed outcomes comparable to those achieved in a previous trial, with higher CD4 scores among newly diagnosed patients.
A single dose of antibody-based treatment can prevent HIV transmission from mother to baby, according to new research. The study found that administering a combination of two antibodies 30 hours after viral exposure prevented SHIV infection in rhesus macaque newborns.
A new study published in Clinical Infectious Diseases found that New Yorkers are being treated sooner after HIV infection, with a median time of 0.2 years (~2.4 months) for those diagnosed in 2015. This reduction coincides with expanded testing and treatment efforts in the city.
A recent study published in E-Clinical Medicine found that about 75% of infants with HIV attained viral suppression on ART, but only 52% sustained it. Early treatment within the first two weeks of life led to similar outcomes as starting within the first two days of life.
A multidisciplinary inpatient team improved viral suppression rates by 30% and increased engagement in care after discharge by 30% for hospitalized HIV patients. The intervention addressed social and medical barriers, reducing future infection rates.
A recent study found that one in three children affected by the outbreak are yet to receive treatment, highlighting the need for urgent government intervention. The average age of children affected is just 3 years old, and most cases were transmitted through reused needles and contaminated blood products.
Researchers found that children with HIV performed poorly on neuropsychological tests, particularly in planning and reasoning abilities, compared to their HIV-negative peers. The disparity worsened over time, highlighting the need for further investigation into the underlying mechanisms of these cognitive challenges.
A new MSU study found that HIV significantly affects children's neuropsychological development, even with early antiretroviral therapy. Children living with HIV showed significant deficits in reasoning and planning abilities compared to their HIV-negative peers.